OMEROmeros Corporation (NASDAQ:OMER) announced that it has entered into a senior credit facility with CRG LP, a healthcare-focused investment firm, to retire the company’s existing credit facility, minimizing restricted cash requirements and providing additional working capital for its advancing pipeline.

The new credit facility consists of an $80 million term loan to be drawn by the company within ten business days and the ability, subject to the satisfaction of certain conditions to access additional funding of up to an aggregate of $45 million in two tranches through December 31, 2017. The company will use approximately $76 million of the loan proceeds to repay its obligations under its existing credit facility. The remaining net proceeds, as well as any of the additional $45 million if borrowed, will be used for general corporate purposes and working capital, including funding advancements in Omeros’ OMS721 Phase 3 and Phase 2 clinical programs, for which the company recently reported positive data in renal diseases and stem cell transplant-associated thrombotic microangiopathies, and Omeros’ other clinical and preclinical programs. With its initial draw of the CRG loan, together with funds on hand and current annualized OMIDRIA revenues and expenses, Omeros anticipates that it will have at least 12 months of operating capital.

With more favorable overall financial terms than the company’s existing credit facility, the CRG secured credit facility has a six-year term with four years (through December 31, 2020) of interest-only payments after which monthly principal and interest payments will be due through the September 30, 2022 maturity date. Omeros has the potential to extend the interest-only period to maturity (i.e., converting the loan to a six-year “bullet”) if an OMIDRIA net revenue milestone is achieved in 2019 or a market capitalization threshold is achieved in 2020. Under the credit facility, Omeros is required to achieve through the end of 2021 either (1) certain minimum total annual revenue amounts (e.g., from OMIDRIA sales, any other product sales, any product partnering revenues, etc.), any shortfall in which can be cured by a cash payment to the lenders equal to that shortfall amount and any prepayment fees due, or (2) a minimum market capitalization threshold. Omeros is also required to maintain $5 million in cash and cash equivalents during the full term of the facility.

“We are excited to be working with Omeros and a management team with a proven track record of success,” stated Luke Düster, managing director of CRG. “As is our standard financing process at CRG, we and our expert consultants performed extensive due diligence on Omeros, OMIDRIA and the rest of the company’s pipeline. The results confirmed that OMIDRIA is a novel and clinically effective drug used in cataract surgery that is well-received in the ophthalmologist community, and that Omeros’ pipeline holds tremendous potential across a number of its programs, which could continue to add significant value to the company over the next few years.”

“We are pleased to partner with the team at CRG,” stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “Their approach has been thoughtful and pragmatic and, as a healthcare-focused investment firm, we expect that CRG will add meaningful value toOmeros. We appreciate both the confidence that CRG has shown in Omeros and their understanding of our business strategy. We look forward to building a long-standing relationship with the CRG team as we continue to execute on that strategy.” (Original Source)

Shares of Omeros are currently trading at $8.10, down $0.06 or -0.74%. OMER has a 1-year high of $16.80 and a 1-year low of $7.20. The stock’s 50-day moving average is $10.23 and its 200-day moving average is $11.38.

On the ratings front, Omeros has been the subject of a number of recent research reports. In a report issued on October 19, Maxim Group analyst Jason Kolbert reiterated a Buy rating on OMER, with a price target of $19, which represents a potential upside of 133% from where the stock is currently trading. Separately, on the same day, FBR’s Thomas Yip reiterated a Buy rating on the stock .

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Thomas Yip have an average loss of 15.4% and 28.1% respectively. Kolbert has a success rate of 26% and is ranked #4056 out of 4188 analysts, while Yip has a success rate of 16% and is ranked #4032.

The street is mostly Bullish on OMER stock. Out of 5 analysts who cover the stock, 5 suggest a Buy rating . The 12-month average price target assigned to the stock is $50.67, which implies an upside of 521% from current levels.

Omeros Corp. engages in the development and commercialization of small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. Its products are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures.